Theranostics is rapidly growing. Alpha-emitting radionuclides increase therapeutic efficacy. Therapeutic radionuclides that decay by emitting β-, such as Lutetium-177, are well established in clinical practice. Radionuclides emitting internal conversion and Auger electrons, e.g. Terbium-161, are approaching translation. Imaging with gamma-emitting radiopharmaceuticals enhance treatment efficacy by personalising radiation doses to individual patients, allowing to maximise tumouricidal therapeutic effects while minimising toxicity to healthy organs. The session outlines the fundamental principles, procedures, and methodologies in imaging, dosimetry and therapy.
Chairperson's introduction
Alpha-emitting radionuclide therapy: the next frontier in targeted cancer treatment
Beta-emitting and Auger electron radiopharmaceuticals: impact and opportunities for targeted imaging and therapy
Gamma emitting imaging: status, success, and future potential in theranostics including dosimetry
Panel discussion: How and who should we treat